EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome

BMC Psychiatry

David Pittrow²  Samuel Elstner³  Helmut Peters⁴  Heike Schieb⁷  Marc Brinkman⁷  Christoph Kretschmar⁶  Michael Huss⁴  Michael Colla⁵  Franziska Gaese¹  Frank Haessler⁸ 

[1]Abt. Psychiatrische Therapie für Menschen mit Geistiger Behinderung, Isar-Amper-Klinikum gGmbH, Klinikum München-Ost, Haar, Germany

[2]Institut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität Carl Gustav Carus Dresden, Dresden, Germany

[3]Berliner Behandlungszentrum der Abteilung für Psychiatrie, Psychotherapie und Psychosomatik, Evangelisches Krankenhaus Königin Elisabeth Herzberge gGmbH, Berlin, Germany

[4]Rheinhessen-Fachklinik Mainz, Kinder- und Jugendpsychiatrie, Mainz, Germany

[5]Experimental and Clinical Research Center, Charité – Campus Berlin Buch & Department of Psychiatry and Psychotherapy, Charité – Campus Mitte, Berlin, Germany

[6]Städt. Krankenhaus Dresden-Neustadt, Zentrum für Kinder- und Jugendmedizin - Sozialpädiatrisches Zentrum, Dresden, Germany

[7]Medizinische Abteilung, Novartis Pharma GmbH, Nürnberg, Germany

[8]Zentrum für Nervenheilkunde, Klinik für Psychiatrie, Neurologie, Psychosomatik und Psychotherapie im Kindes- und Jugendalter, Universitätsmedizin Rostock, Rostock, Germany

关键词: Caregiver burden;    Quality of life;    Ambulatory setting;    Outcomes;    Health care;    Patient-related outcomes;    Longitudinal;    Observational trial;   

Others  :  1123857
DOI  :  10.1186/1471-244X-13-339

 received in 2013-05-27, accepted in 2013-12-16,  发布年份 2013

【 摘 要 】

Background

Fragile X syndrome (FXS), caused by a mutation of the FMR1 gene on the X chromosome, is the most common inherited form of intellectual disability and autism spectrum disorders. Comprehensive data are lacking, however, on the characteristics and management patients with FXS in Germany.

Methods/design

EXPLAIN is a prospective, observational, longitudinal registry with a non-probability sampling approach. It collects data on patient characteristics, therapeutic interventions, psychosocial parameters (including those of family members and caregivers), quality of life of caregiver and patient, caregiver burden, and health economic parameters, such as hospitalisation time. It is designed to include data from 300 patients in ambulatory care from about 50 centres that employ psychiatrists, paediatricians, neurologists, and other relevant specialists, in Germany. The study was initiated in March, 2013. Patients will be followed for at least two years.

Discussion

The registry is expected to provide much-needed data on the characteristics and management of patients with FXS in Germany. It will also allow comparisons with other countries, and will enable gap analyses based on current guidelines for management of these patients.

Trial registration

The ClinicalTrials.gov identifier is NCT01711606.

【 授权许可】

   
2013 Haessler et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wang T, Bray SM, Warren ST: New perspectives on the biology of fragile X syndrome. Curr Opin Genet Dev 2012, 22(3):256-263.
• [2]de Vries BB, Mohkamsing S, van den Ouweland AM, Mol E, Gelsema K, van Rijn M, Tibben A, Halley DJ, Duivenvoorden HJ, Oostra BA, et al.: Screening for the fragile X syndrome among the mentally retarded: a clinical study. The collaborative fragile X study group. J Med Genet 1999, 36(6):467-470.
• [3]Carter MT, Scherer SW: Autism spectrum disorder in the genetics clinic: a review. Clin Genet 2013, 83(5):399-407.
• [4]Lewis P, Abbeduto L, Murphy M, Richmond E, Giles N, Bruno L, Schroeder S: Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res 2006, 50(Pt 7):532-545.
• [5]Barnes E, Roberts J, Long SH, Martin GE, Berni MC, Mandulak KC, Sideris J: Phonological accuracy and intelligibility in connected speech of boys with fragile X syndrome or Down syndrome. J Speech Lang Hear Res 2009, 52(4):1048-1061.
• [6]Deshpande PS, Coffey DB: Fragile X syndrome and attention-deficit/hyperactivity disorder symptoms. J Child Adolesc Psychopharmacol 2011, 21(6):639-642.
• [7]Baker JK, Seltzer MM, Greenberg JS: Behaviour problems, maternal internalising symptoms and family relations in families of adolescents and adults with fragile X syndrome. J Intellect Disabil Res 2012, 56(10):984-995.
• [8]McCary LM, Roberts JE: Early identification of autism in fragile X syndrome: a review. J Intellect Disabil Res 2013, 57(9):803-814.
• [9]Gabis LV, Baruch YK, Jokel A, Raz R: Psychiatric and autistic comorbidity in fragile X syndrome across ages. J Child Neurol 2011, 26(8):940-948.
• [10]Sabaratnam M, Murthy NV, Wijeratne A, Buckingham A, Payne S: Autistic-like behaviour profile and psychiatric morbidity in Fragile X Syndrome: a prospective ten-year follow-up study. Eur Child Adolesc Psychiatry 2003, 12(4):172-177.
• [11]Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB: Seizures in fragile X syndrome: characteristics and comorbid diagnoses. Am J Intellect Dev Disabil 2010, 115(6):461-472.
• [12]Sofocleous C, Kolialexi A, Mavrou A: Molecular diagnosis of Fragile X syndrome. Expert Rev Mol Diagn 2009, 9(1):23-30.
• [13]Rueda JR, Ballesteros J, Tejada MI: Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol 2009, 9:53. BioMed Central Full Text
• [14]Bailey DB Jr, Raspa M, Bishop E, Olmsted M, Mallya UG, Berry-Kravis E: Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr 2012, 33(1):62-69.
• [15]Martin GE, Ausderau KK, Raspa M, Bishop E, Mallya U, Bailey DB Jr: Therapy service use among individuals with fragile X syndrome: findings from a US parent survey. J Intellect Disabil Res 2013, 57(9):837-849.
• [16]Hagerman R, Lauterborn J, Au J, Berry-Kravis E: Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 2012, 54:297-335.
• [17]Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, Gomezmancilla B, et al.: AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 2011, 42(3):311-317.
• [18]Giangreco CA, Steele MW, Aston CE, Cummins JH, Wenger SL: A simplified six-item checklist for screening for fragile X syndrome in the pediatric population. J Pediatr 1996, 129(4):611-614.
• [19]Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale–preliminary report. Psychopharmacol Bull 1973, 9(1):13-28.
• [20]Kubinger K: The intelligence test-battery AID 2 as a prototypical globalized test. Testing International 2008, 19:13-14.
• [21]Petermann F, Petermann U: HAWIK-IV. 3rd edition. Bern, Switzerland: Huber Verlag; 2010.
• [22]Melchers P, Preuß U: Kaufman Assessment Battery for Children. 8th edition. Frankfurt/Main, Germany: Pearson Assessment; 2009.
• [23]Harris SH: An evaluation of the Snijders-Oomen nonverbal intelligence scale for young children. J Pediatr Psychol 1982, 7(3):239-251.
• [24]Newton JT, Sturmey P: The aberrant behaviour checklist: a British replication and extension of its psychometric properties. J Ment Defic Res 1988, 32(Pt 2):87-92.
• [25]Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Greiner W, Gusi N, Herdman M, et al.: Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010, 19(6):875-886.
• [26]Loyd BH, Abidin RR: Revision of the parenting stress index. J Pediatr Psychol 1985, 10(2):169-177.
• [27]Honigfeld G: NOSIE–30: history and current status of its use in pharmacopsychiatric research. Mod Probl Pharmacopsychiatry 1974, 7:238-263.
• [28]Honigfeld G, Gillis RD, Klett CJ: NOSIE-30: a treatment-sensitive ward behavior scale. Psychol Rep 1966, 19(1):180-182.
• [29]Linden M, Baron S, Muschalla B: Mini-ICF-Rating für Aktivitäts- und Partizipationsstörungen bei psychischen Erkrankungen. Gottingen, Germany: Hogreve Verlag; 2013.
• [30]International Federation of Pharmaceutical Manufacturers and Associations (IFPMA): MedDRA (Medical Dictionary for Regulatory Activities). Internet. : ; http://www.meddra.org/ webcite. Accessed on 18 December 2013
• [31]Federal Institute for Drugs and Medical Products (BfArM): Recommendations of the Federal Institute for Drugs and Medical Products and the Paul Ehrlich Institute on the planning, conduct and analysis of post marketing studies dated 7 July 2010. Internet. : ; http://www.bfarm.de/DE/Arzneimittel/zul/klinPr/nichtInterventPruef/nichtInterventPruef-home.html webcite. Accessed on 18 December 2013
• [32]German Association of Research-based Pharmaceutical Companies (Verband der forschenden Arzneimittelhersteller VFA): Rules for publication of post-marketing surveillance studies. : ; Internet: http://www.vfa.de/en/articles/art-2007-11-002.html webcite. Accessed on 18 December 2013
• [33]Hartley SL, Seltzer MM, Raspa M, Olmstead M, Bishop E, Bailey DB: Exploring the adult life of men and women with fragile X syndrome: results from a national survey. Am J Intellect Dev Disabil 2011, 116(1):16-35.
• [34]Bailey DB, Raspa M, Olmsted MG: Using a parent survey to advance knowledge about the nature and consequences of fragile X syndrome. Am J Intellect Dev Disabil 2010, 115(6):447-460.
• [35]Bailey DB, Raspa M, Holiday D, Bishop E, Olmsted M: Functional skills of individuals with fragile x syndrome: a lifespan cross-sectional analysis. Am J Intellect Dev Disabil 2009, 114(4):289-303.